Monogram Orthopaedics Inc ( (MGRM) ) has issued an update.
On March 17, 2025, Monogram Technologies Inc. announced that it received FDA 510(k) clearance for its Monogram mBôs™ TKA System, allowing it to market the device under specific regulatory provisions. This clearance marks a significant milestone for the company, highlighting years of innovation and teamwork in advancing orthopedic robotics. The system is designed to enhance safety, efficiency, and accuracy in robotic-assisted total knee arthroplasty and is positioned for future expansion into other orthopedic applications. The company is preparing for commercialization and aims to establish clinical experience with key surgeons to demonstrate the system’s advantages. This development opens new domestic and international opportunities, supporting Monogram’s strategic growth and long-term commercialization strategy.
More about Monogram Orthopaedics Inc
Monogram Technologies Inc. is an AI-driven robotics company focused on improving human health, particularly in orthopedic surgery. The company is developing solutions for patient-optimized orthopedic implants using 3D printing, advanced machine vision, AI, and next-generation robotics. Monogram aims to produce and market robotic surgical equipment, orthopedic implants, and related tools for reconstructive joint replacement procedures.
YTD Price Performance: -2.10%
Average Trading Volume: 47,998
Technical Sentiment Consensus Rating: Strong Buy
For detailed information about MGRM stock, go to TipRanks’ Stock Analysis page.